TMCnet News
RetroSense Therapeutics' Clinical-Stage Development Program to Restore Vision Wins Multiple AwardsRetroSense Therapeutics, a privately-held, clinical-stage biotechnology company, announced today that Therapeutic Area Partnerships has selected RetroSense lead compound, RST-001, as a "Top Project to Watch: Most Licensable Products" for the third consecutive year. RetroSense recently also won the "Deals of the Year" Research Award from MLive and Ann Arbor News. RetroSense Therapeutics is at the forefront of developing optogenetic therapies for vision restoration. In August 2015, RetroSense's RST-001 received clearance from the FDA to begin clinical trials and patient recruitment is currently underway. In October 2014, the FDA granted Orphan Drug designation for RST-001 for the treatment of retinitis pigmentosa, a genetic disease characterized by deteriorating vision and blindness. Sean Ainsworth, CEO of RetroSense Therapeutics, will be presenting a company overview in the "Advanced Therapeutics" category at the 10th Annual Therapeutic Area Partnerships "Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees consider among the most attractive opportunities the industry has to offer," said Marc Wortman, Editorial Director, Therapeutic Area Partnerships. "Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level biotechnology and pharmaceutical partnering opportunities, potential for new opportunities beyond initial indications and corporate stability. As the industry leader in strategic analysis and transaction tracking, our main goal is to give these companies exposure to potential investors, partners, and acquirers." "We are pleased to have been selected as a "Top Project to Watch in the Most Licensable Products" category for the third consecutive year," said Mr. Ainsworth. "We have made great strides in the development of RST-001 and are excited to be moving forward with our clinical study." At the 2015 Ann Arbor News/MLive Media Group "Deals of the Year" ceremony, RetroSense was recognized with the Research Award for its potentially groundbreaking and sight-restoring therapy. Earlier this year, the Company was also recognized as, "the most innovative ACA angel invested company for 2015", with the "Villalobos Award". The announcement further stated, "RetroSense Therapeutics is a well-deserved winner. Its innovations could make a huge difference in the lives of those blinded with retinal disorders." About RetroSense Therapeutics RetroSense Therapeutics is a privately-held, clinical-stage biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD (News - Alert)). There are currently no FDA approved drugs to improve or restore vision in patients with these retinal degenerative conditions. The Company's approach to using optogenetics in vision restoration is based on pioneering, proprietary research conducted at Wayne State University and Massachusetts General Hospital. RetroSense has worldwide exclusive rights to the relevant intellectual property from both institutions. RetroSense is led by a team of seasoned veterans with deep experience in taking products from the discovery stage through clinical trials. For more information about RetroSense Therapeutics, visit http://www.retro-sense.com/. View source version on businesswire.com: http://www.businesswire.com/news/home/20151118006396/en/ |
